MA-SKYHOOK
Alps Alpine, a leading manufacturer of electronic components and automotive infotainment systems, has chosen Skyhook, the worldwide independent leader in location technology, as its location services provider. Alps Alpine will now utilize Skyhook’s Precision Location positioning technology in their IoT devices and services.
With Alps Alpine's vast experience in electronics coupled with the extensive location positioning expertise from Skyhook, Alps Alpine will be able to create a great user experience for enterprises and institutions that need to know the exact location of devices in order to manage and operate them.
Alps Alpine’s involvement in the IoT industry is extensive, and the addition of Skyhook’s technology ensures that customers receive accurate and precise positioning from all of their IoT devices.
Skyhook’s ability to provide accurate location regardless of environmental interferences, such as in underground tunnels or densely populated cities, is incredibly valuable when analyzing efficient transportation of materials, ensuring timeliness of the supply chain, and locating large pallets or bins within a warehouse. These capabilities will benefit Alps Alpine devices and their customers. Skyhook’s Precision Location hybrid positioning system locates devices using Wi-Fi, GNSS and Cell signals, ensuring that all devices, like asset trackers, can be located in all environments. The solution provides the ability to locate devices in LPWAN limited networks like Sigfox using 12 bytes of payload only, in an extremely power efficient manner, allowing devices to be in service for longer periods with a single battery.
“Alps Alpine believes that the high-precision location information provided by Skyhook will increase the value of our long-life IoT devices,” said Koichi Endo, Director Senior Vice President Deputy CTO, New Business and Engineering, Alps Alpine.
“We are proud to partner with Alps Alpine to provide Skyhook’s hybrid positioning system to an array of their products”, said Craig Waggy, CEO of Skyhook. “IoT devices and services benefit greatly from the accurate and resource efficient location service that is at the core of what Skyhook delivers.”
About Skyhook:
Skyhook is the worldwide independent leader in location technology, operating the world's largest independent location network, consisting of 5.1 billion geolocated Wi-Fi hotspots and 200 million cell towers. Skyhook processes tens of billions of location transactions, serving devices, apps, wearables, brands and advertising platforms with precise and accurate location data and intelligence. Skyhook, through its parent company Skyhook Holding, Inc., operates as a wholly owned subsidiary of Liberty Broadband Corporation. To learn more visit www.skyhook.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005129/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FIM Partners and Loomis Sayles Announce Transition of Global Emerging Market Equities Team6.11.2025 14:00:00 CET | Press release
FIM Partners today announced it has entered into an agreement with Loomis, Sayles & Company, to acquire the Global Emerging Market Equities (GEM) investment team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106799715/en/ Overview of the GEM Team and FIM Led by Ashish Chugh, Portfolio Manager and Head of Global Emerging Market Equities, the GEM Team follows a high conviction investment philosophy anchored in deep, fundamental research and a private equity-style approach to diligence and ownership. The team invests in high quality companies and those transitioning toward higher quality, leveraging its proprietary insights to identify long-term value creation opportunities across emerging markets. With an active, bottom-up, benchmark-agnostic strategy, the team builds high-conviction, concentrated, quality-focused portfolios that reflect a true ownership mindset. Founded in 2008, FIM Partners is a leading asset manager fo
IFCO’s circular model delivers global impact: Five years of progress marked with 2025 ESG report6.11.2025 14:00:00 CET | Press release
Over 10 billion single-use boxes replaced with reusable packaging in global fresh grocery supply chains IFCO, a global leader in reusable packaging containers (RPCs) for fresh food, today published its ESG Report 2025, marking the successful completion of its five-year sustainability strategy, Thriving in the Circular Economy. Over the last five years, IFCO has advanced every one of its 18 ESG goals, delivering measurable progress for the planet, people, partners, and customers while laying the groundwork for the next iteration of its sustainability objectives. The ESG Report 2025 confirms IFCO’s position as a global leader in circular packaging and highlights the role of reuse in addressing some of the sector’s most pressing challenges. Since IFCO’s founding in 1992, it has dedicated itself to eliminating packaging and food waste in the fresh grocery supply chain, enhancing efficiencies across the value chain and sharing the resulting long-term value with stakeholders. With operations
Debiopharm Takes a Step Forward for Children With CPP: Enrollment Completion for the Phase III Trial Evaluating the First Ever Yearly Injectable Triptorelin Formulation6.11.2025 14:00:00 CET | Press release
LIBELULATM trial completed enrollment of Central Precocious Puberty (CPP) patients in North and South America, advancing the path for Debio 4326, a triptorelin injectable 12-month extended-release formulation Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality of life, today announced the successful completion of patient enrollment in its open-label, single-arm, multi-center Phase III study (NCT06129539) ‘A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULATM)’. The completion of enrollment is a significant milestone for the development of Debio 4326, a unique injectable, biodegradable 12-month extended-release formulation of the established treatment, triptorelin. The LIBELULATM trial is being conducted across the United States, Argenti
U.K. Continues to Lead Europe in Shareholder Activism with 44% Year-on-Year Surge, According to Diligent Market Intelligence6.11.2025 13:00:00 CET | Press release
As the U.K. Market Fuels Growing Interest from Domestic and International Activists, Investors Have Adapted their Approach to Gain Access to Boardrooms in Germany and Italy The U.K. remains Europe’s most active market for shareholder activism, with a 44% year-on-year increase in targeted companies, according to the Corporate Governance in Europe 2025report by Diligent Market Intelligence (DMI). Between September 2024 and August 2025, 52 U.K. companies faced activism, compared to 36 over the same timeframe in 2024, underscoring the market’s heightened shareholder engagement. “The U.K. remains the primary driver of public-facing engagement in Europe, with other European markets increasingly witnessing similar strategies when behind-the-scenes efforts fail,” said Josh Black, Editor-in-Chief, Diligent Market Intelligence. “Activism in Europe runs the full gamut from hostile media campaigns to more private engagements but there is no doubt that boards should prepare for anything in what loo
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates6.11.2025 12:00:00 CET | Press release
Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024Global BRUKINSA® (zanubrutinib) revenues increased 51% to $1.0 billion versus third quarter 2024Diluted GAAP Earnings per American Depository Share (ADS) of $1.09, non-GAAP diluted Earnings per ADS of $2.6547 abstracts accepted at American Society of Hematology (ASH) Annual Meeting BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. “These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,” said John V. Oyler, Co-Founder, Chairman and CEO at BeOne. “BRUKINSA is now the global revenue leader in the BTKi class, supported by long-term efficacy and safety data and a growing body of evidence reinforcing its scientific hypothesis of sustained BTK inhibition. Our late-stage hematology portfolio continues
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
